WCN26-8528 FERRIC CARBOXYMALTOSE VERSUS FERRIC DERISOMALTOSE: IMPACT ON HYPOPHOSPHATEMIA - A CASE REPORT

Read full text Summarise with VIRAT
Authors: Andreja Marn Pernat, Neža Četina
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Intravenous (i.v.) iron therapy is an effective and widely used treatment for iron deficiency anemia, but may cause hypophosphatemia. This is usually transient and asymptomatic, but with repeated administrations, severe and prolonged hypophosphatemia with serious clinical consequences may develop. The mechanism involves increased fibroblast growth factor 23, which promotes renal phosphate excretion and suppresses calcitriol synthesis, leading to secondary hyperparathyroidism that further enhances phosphate loss.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Iron Metabolism and Disorders Erythropoietin and Anemia Treatment

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103853–103853
Publication date
25 March 2026
Language
EN